Knight Therapeutics Inc. (TSE:GUD – Free Report) – Equities researchers at Raymond James issued their Q4 2025 earnings per share (EPS) estimates for Knight Therapeutics in a note issued to investors on Thursday, March 20th. Raymond James analyst M. Freeman anticipates that the company will earn $0.01 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.04 EPS.
Other research analysts have also recently issued research reports about the company. Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 11th. Canaccord Genuity Group downgraded shares of Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, March 21st. Finally, Stifel Nicolaus increased their target price on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of C$7.48.
Knight Therapeutics Stock Performance
Shares of GUD opened at C$6.01 on Monday. The firm has a market capitalization of C$607.91 million, a P/E ratio of -20.06, a P/E/G ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 52 week low of C$5.09 and a 52 week high of C$6.45. The stock has a 50 day moving average price of C$5.71 and a two-hundred day moving average price of C$5.59. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36.
Insider Activity at Knight Therapeutics
In other news, insider Sime Armoyan sold 92,200 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of C$6.15, for a total transaction of C$567,030.00. Over the last three months, insiders sold 3,143,300 shares of company stock valued at $19,733,740. 45.62% of the stock is owned by insiders.
Knight Therapeutics Company Profile
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Further Reading
- Five stocks we like better than Knight Therapeutics
- What is the Hang Seng index?
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Stock Sentiment Analysis: How it Works
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Learn Technical Analysis Skills to Master the Stock Market
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
